Conference News

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring

CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring

By

A new method of measuring lean body mass accounts for changes in body composition, enabling improved disease staging and monitoring of therapy.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

By

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

By

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia

By

Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

By

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Rates of Colorectal Cancer Are Increasing in Younger Patients, Despite an Overall Decline

By

Reasons for the continuing increase in cases of young-onset colorectal cancer, despite a decline in the overall rate of the disease in recent years, are unclear.

Chemotherapy and Radiation Prior to Surgery Improves Outcomes in Patients With Pancreatic Cancer

Chemotherapy and Radiation Prior to Surgery Improves Outcomes in Patients With Pancreatic Cancer

By

Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.

Early Palliative Care Improves Quality of Life for Family Caregivers of Patients With Cancer

Early Palliative Care Improves Quality of Life for Family Caregivers of Patients With Cancer

By

The introduction of palliative care shortly after a patient is diagnosed with cancer is associated with improved quality of life.

Precision Medicine Linked to Better Outcomes in Early Trials

Precision Medicine Linked to Better Outcomes in Early Trials

By

Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

By

Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.

Radiation Therapy Better Than Chemotherapy for Stage IIA Testicular Cancer

By

Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.

Increased Risk of Noncancer Deaths Associated with Stereotactic Body Radiation Therapy for Lung Cancer

By

High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.

Immunotherapy-radiation Combination Destroys Tumors Both Within and Outside the Radiation Field

Immunotherapy-radiation Combination Destroys Tumors Both Within and Outside the Radiation Field

By

Adding an immune system-strengthening compound to radiation therapy can extend the immune response that the radiation therapy induces, so that both irradiated tumor sites and tumors outside the radiation field are affected.

Survival in Head and Neck Cancer Increased With Nivolumab Over Chemotherapy

By

The immunotherapy drug nivolumab conferred a survival benefit in patients with head and neck cancer over standard chemotherapy.

New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer

New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer

By

Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.

Necitumumab With Chemotherapy Beneficial for Patients With EGFR-expressing NSCLC

Necitumumab With Chemotherapy Beneficial for Patients With EGFR-expressing NSCLC

By

The most benefit from adding necitumumab to chemotherapy with gemcitabine and cisplatin occurred for patients whose advanced squamous NSCLC expressed EGFR.

Tumor Regression Achieved With LOXO-101 in Phase 1 Study

By

Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.

Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC

Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC

By

Treatment benefit can be predicted through genotyping from blood plasma, according to several studies presented at ELCC 2016; however, plasma tests are unlikely to fully replace tissue biopsies.

Chronic HBV Treatment Linked to Increased Rates of Colorectal and Cervical Cancer

Chronic HBV Treatment Linked to Increased Rates of Colorectal and Cervical Cancer

By

A potential link between long-term oral treatment with nucleos(t)ide analogues for chronic hepatitis B virus (HBV) and an increased risk of colorectal and cervical cancers was demonstrated.

Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors

Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors

By

Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.

Oral Chemotherapy Care Model Improves Safety, Quality Through Increased Collaboration

Oral Chemotherapy Care Model Improves Safety, Quality Through Increased Collaboration

By

A nurse-facilitated oral chemotherapy care model has improved delivery times, patient satisfaction, and co-pay support at a Connecticut cancer hospital.

Follow-up Calls, Clinician Assessment May Identify Patients Who Need Adherence Support

Follow-up Calls, Clinician Assessment May Identify Patients Who Need Adherence Support

By

Follow-up telephone calls and clinician assessment may be an effective strategy to identify early which patients require support with adhering to oral cancer therapy.

Precision Medicine Resource Center Improves Patient Education

Precision Medicine Resource Center Improves Patient Education

By

A nurse-managed precision cancer treatment education resource center may improve information dissemination about genomic health and targeted therapy.

Inpatient Oral Chemotherapy Administration Process Developed to Comply With Safety Standards

Inpatient Oral Chemotherapy Administration Process Developed to Comply With Safety Standards

By

Instituting a Chemotherapy Safety Committee and developing an administration process successfully standardized the inpatient oral chemotherapy administration process.

Formal Nursing Practice Promotes Patient Safety With Oral Chemotherapy

Formal Nursing Practice Promotes Patient Safety With Oral Chemotherapy

By

A formal nursing practice was developed to promote patient safety and adherence with oral chemotherapy.

Routine Screen Reduced Hospital-acquired Pneumonia on an Oncology Telemetry Unit

Routine Screen Reduced Hospital-acquired Pneumonia on an Oncology Telemetry Unit

By By

Implementation of the Massey Bedside Swallowing Screen and strict oral care regimens in high-risk patients reduced the rate of hospital-acquired pneumonia (HAP) at an oncology treatment center.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs